DEXCOM, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.2 USD | -2.22% |
|
-0.73% | -10.27% |
| Jun. 26 | Wall Street: up, on the edge, despite rates | CF |
| Jun. 25 | Out with AI, in with defensive stocks |  |
Financials (USD)
| Sales 2024 * | 4.33B | Sales 2025 * | 5.16B | Capitalization | 45.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 729M | Net income 2025 * | 908M | EV / Sales 2024 * | 10.8 x |
| Net Debt 2024 * | 1.43B | Net Debt 2025 * | 994M | EV / Sales 2025 * | 8.96 x |
| P/E ratio 2024 * |
62.9
x | P/E ratio 2025 * |
51.4
x | Employees | 9,550 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on DexCom, Inc.
More recommendations
More press releases
| 1 day | -2.62% | ||
| 1 week | -1.03% | ||
| Current month | -2.09% | ||
| 1 month | -4.77% | ||
| 3 months | -20.67% | ||
| 6 months | -14.36% | ||
| Current year | -10.54% |
1 week
109.81
113.83
1 month
108.71118.80
Current year
108.71142.00
1 year
74.75142.00
3 years
66.89164.86
5 years
34.57164.86
10 years
8.67164.86
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 07-10-31 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 18-08-31 |
| Chief Tech/Sci/R&D Officer | 47 | 22-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 09-11-19 |
Mark Foletta
BRD | Director/Board Member | 63 | 14-11-18 |
Eric Topol
BRD | Director/Board Member | 69 | 09-07-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.46% | 21 M€ | +10.60% | - | |
| 1.04% | 15 M€ | -5.13% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-08 | 111.3 | -2.08% | 632 740 |
| 24-07-05 | 113.7 | +2.51% | 1,347,262 |
| 24-07-03 | 110.9 | -1.40% | 1,353,061 |
| 24-07-02 | 112.5 | +0.29% | 1,778,550 |
| 24-07-01 | 112.2 | -1.07% | 2,583,626 |
Delayed Quote Nasdaq, July 08, 2024 at 11:32 am EDT
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
113.7
USD
Average target price
150.3
USD
Spread / Average Target
+32.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.54% | 45.21B | |
| -7.07% | 181B | |
| -6.66% | 99.52B | |
| -7.08% | 65.82B | |
| +8.63% | 43.85B | |
| +11.01% | 42.17B | |
| +10.04% | 28.75B | |
| +18.54% | 25.39B | |
| -8.70% | 23.5B | |
| -12.42% | 22.22B |
- Stock Market
- Equities
- DXCM Stock
